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Background: Familial dilated cardiomyopathy (DCM) is a monogenic disorder typically
inherited in an autosomal dominant pattern. We have identified two Finnish families with
familial cardiomyopathy that is not explained by a variant in any previously known
cardiomyopathy gene. We describe the cardiac phenotype related to homozygous
truncating GCOM1 variants.
Methods and Results: This study included two probands and their relatives. All the
participants are of Finnish ethnicity. Whole-exome sequencing was used to test the
probands; bi-directional Sanger sequencing was used to identify the GCOM1 variants
in probands’ family members. Clinical evaluation was performed, medical records and
death certificates were obtained. Immunohistochemical analysis of myocardial samples
was conducted. A homozygousGCOM1 variant was identified altogether in six individuals,
all considered to be affected. None of the nine heterozygous family members fulfilled any
cardiomyopathy criteria. Heart failure was the leading clinical feature, and the patients may
have had a tendency for atrial arrhythmias.
Conclusions: This study demonstrates the significance of GCOM1 variants as a cause of
human cardiomyopathy and highlights the importance of searching for new candidate
genes when targeted gene panels do not yield a positive outcome.
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INTRODUCTION
Dilated cardiomyopathy (DCM) is defined by reduced ejection
fraction and dilation of the left ventricle in the absence of other
causative factors such as abnormal loading conditions or severe
coronary artery disease. (Elliott et al., 2008). Clinical onset is
typically in adulthood but may also take place in infancy.
(Hershberger et al., 2009). Estimates of DCM prevalence range
between 1:250 and 1:3,000. (Codd et al., 1989; Mestroni et al.,
1999; Hershberger et al., 2013). Phenotypic expression and
severity vary greatly, even within the same family.
(Hershberger et al., 2010). Patients typically present with
advanced disease, including severe heart failure, arrhythmias,
and sudden cardiac death (SCD), but the disease may also be
asymptomatic while developing. (Hershberger et al., 2010).
Familial DCM is a monogenic disorder primarily inherited in
an autosomal dominant pattern. (Hershberger et al., 2010;
Hershberger et al., 2013; McNally et al., 2013). Genetic
etiology is broad with at least 50 genes associated. (McNally
et al., 2013).
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is
a progressive myocardial disease that usually affects the right
ventricle (RV), but it can also affect the left ventricle (LV),
producing a DCM phenotype. (Elliott et al., 2008; Marcus
et al., 2010). ARVC is characterized histologically by fibrofatty
replacement of the myocardial tissue and clinically by right
ventricular dysfunction, ventricular arrhythmias, and risk of
SCD. (Elliott et al., 2008; Marcus et al., 2010; Basso et al.,
2012). The estimated prevalence of ARVC is 1:5,000, but it is
a significant cause of SCD especially in young people and athletes.
(Elliott et al., 2008). The majority of ARVC pathological variants
are reported with autosomal dominant inheritance patterns, and
there is some overlap with DCM genetic background. (Jacoby and
McKenna, 2012; Campuzano et al., 2013; Hershberger et al.,
2013).
As DCM and ARVC sometimes overlap in phenotypic
expression, it can be challenging to distinguish these subtypes
clinically. As a term, ARVC does not fully reflect the spectrum of
associated phenotypes, especially the left-dominant and
biventricular disease subtypes. This has led to a change in
nomenclature, and the concept of arrhythmogenic
cardiomyopathy (AC) has been proposed, as it better reflects
the broad spectrum of the disease. (Towbin et al., 2019; Corrado
et al., 2020). Genetic testing is recommended when inherited
cardiomyopathies are suspected. (Hershberger et al., 2018;
Musunuru et al., 2020). In the future, genetic testing may have
a bigger role in differential diagnosis and specifying the
cardiomyopathy subtype. Knowing the specific subtype could
help better predict the prognosis and guide clinical decision
making.
The GRINL1A complex transcription unit (CTU) in
chromosome 15 comprises two neighboring genes,
upstream gene MYZAP, and downstream gene POLR2M.
(Roginski et al., 2001; Roginski et al., 2004; Hu et al.,
2006; Seeger et al., 2010; Roginski et al., 2018). MYZAP
encodes the protein Myozap that is mainly expressed in
myocardial tissue. Seeger et al. noticed that a knockdown
of MYZAP in zebrafish leads to cardiomyopathy with severe
systolic dysfunction and no significant enlargement. (Seeger
et al., 2010). POLR2M encodes the protein that is the 13th
subunit of RNA polymerase II. (Hu et al., 2006). The GCOM1
combined gene utilizes exons from both MYZAP and
POLR2M as well as its own exons, resulting in amino acid
translations that contain residues that are not present in
either of the CTU genes. (Roginski et al., 2004; Roginski
et al., 2018) (Figure 1).
We have identified two Finnish families with familial
cardiomyopathy not explained by variants in previously
known cardiomyopathy genes. In this study, we describe the
cardiac phenotype related to homozygous truncation of GCOM1
variants in these two families.
SUBJECTS AND METHODS
Subjects
This study included two probands who were patients at Helsinki
University Hospital. All available family members were
examined. All participants are of Finnish ethnicity. Clinical
data were collected from all the available hospital records.
Pedigrees were drawn and family history was obtained. When
possible, death certificates and autopsy records were obtained.
Most patients were evaluated as part of this study by 12-lead ECG,
echocardiography, and physical examination. In some cases,
stress-test, Holter-monitoring, cardiac magnetic resonance
imaging (CMR), endomyocardial biopsy (EMB), or positron
emission tomography-computed tomography (PET-CT) were
performed.
DCM was diagnosed using the following criteria: systolic
dysfunction (left ventricular ejection fraction [LVEF] <45%)
and dilatation of the left ventricle (left ventricular end-
diastolic diameter [LVEDD] >27 mm/ m2), in the absence
of severe coronary artery disease or abnormal loading
conditions such as valvular disease and hypertension.
Family members were considered to be possibly affected if
they had at least one of the following: atrial fibrillation (AF) at
age of under years, conduction defects, left ventricular
dilatation, or systolic dysfunction. In Holter-monitoring
ventricular extrasystoles (VES) > 500/24 h or
supraventricular extrasystoles (SVES) > 1500/24 h were
considered significant. The patient with ARVC was
diagnosed in the 1990s and early 2000s using the existing
diagnostic criteria available at that time.
All the participants in this study gave written informed
consent. This study has been approved by the Ethical Review
Committee of The Department of Medicine, University of
Helsinki (HYKS 26/99, HYKS 16/99, HYKS 17/99, HYKS 19/
2000, HYKS 8/2000, HUS/3225/2018 Dnro 307/13/January 03,
2011, TMK11§274,December 16, 2015). Statistics Finland,
Finnish Institute for Health and Welfare, and the Ministry of
Social Affairs and Health have given the permission to obtain
clinical data from deceased patients for research purposes (THL/
1078/5.05.00/2020). This study complies with the Declaration of
Helsinki.
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Molecular Genetic Studies
The genetic testing was carried out at the Blueprint Genetics
laboratory at Espoo, Finland. Whole-exome sequencing (WES)
was used to test both probands. Bi-directional Sanger sequencing
was used to screen the familial GCOM1 in probands’ family
members. In addition, a Blueprint Genetic Comprehensive
Cardiology Panel including 217 nuclear genes and
mitochondrial genome was used to test I.I and I.2 of Family 1.
Mutation nomenclature is based on GenBank accession
NM_001285900.3 (GCOM1) with nucleotide one being the
first nucleotide of the translation initiation codon ATG. The
pathogenicity of these GCOM1 variants was evaluated using the
American College of Medical Genetics and Genomics (ACMG)
classification scheme. (Richards et al., 2015).
Sequencing
When necessary, a bead-based method was used to extract the
genomic DNA from the biological sample and electrophoretic
methods were used to assess DNA quantity and quality. After
quality assessment, non-contact isothermal sonochemistry
processing was used to randomly fragment the qualified
genomic DNA. Sequencing adapters were ligated to both ends
of DNA fragment to prepare sequencing libraries. A bead-based
method was used to size-select sequencing libraries to ensure the
optimal template size and were amplified using polymerase chain
reaction (PCR). A hybridization-based target capture method was
used to target intronic targets and exons. The quality control of
the completed sequencing library was made by confirming the
appropriate template size and quantity and ensuring the absence
of leftover primers and adapter-adapter dimers. Illumina’s
sequencing-by-synthesis method using paired-end sequencing
(150 by 150 bases) was used to sequence the sequencing
libraries after they had passed the quality control. The
sequencing instrument used Illumina’s trademarked software
to carry out primary data analysis, which included converting
images into base calls and associated quality scores, the final
output being the generated CBCL files.
Histology and Immunohistochemistry
Histological samples were analyzed from patients in Family 1
(II.1), and Family 2 (II.4, II.9, II.10). Other myocardial samples
were used as control tissue. Samples of F1 II.4 and F2 II.4 were
obtained from Helsinki Biobank.
Three μm sections were cut from formalin-fixed paraffin-
embedded specimens. Antigen retrieval was done in a
decloaking chamber (Biocare Medical (Decloaking
Chamber, 2021)) 20 min at +95°C in EnVision FLEX Target
Retrieval Solution (low pH antigen retrieval solution, Dako,
product number K8005). After blocking of endogenous
peroxidase with BLOXALL® blocking solution (Vector
laboratories, product number SP-6000–100 (Peroxidase
Blocking Solution, 2021)), sections were incubated with
antibody detecting MYOZAP-GCOM1 (Origene, catalogue
number TA320110, final IgG concentration 0.2 μg/ ml). The
antibody detects an 18 amino acid (aa) sequence near the
carboxy terminus of MYOZAP (407-425aa). Dako REAL
FIGURE 1 | Four GRINL1A transcripts. Abbreviations: aa for amino acid, SEG for low complexity region; NDS for asparagine-linked glycosylation site; BRLZ for
BRLZ leucine zipper; SP for signal peptide. The twoGCOM1 variants are marked in red; Arg130* forGCOM1 c.388C > T, p.(Arg130*) and Lys384* forGCOM1 c.1150 A
> T, p.(Lys384*) (Roginski et al., 2004; Seeger et al., 2010; Roginski et al., 2018).
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EnVision Detection System was used for visualization of the
primary antibody (Dako, product number K5007). Mayer’s
haematoxylin (Dako, product number S3309) was used as
counter stain. Substituting primary antibody with rabbit
non-immune IgG (Vector laboratories, affinity purified
rabbit IgG, catalogue number I-1000 (Rabbit IgG, 2021)) at
same IgG-concentration was used as a negative control for the
primary antibody. Omitting primary antibody was used for
ruling out unspecific staining by secondary antibody. Stained




We identified two homozygous truncatingGCOM1 variants, each
in a different family, in patients presenting with cardiomyopathy.
A homozygous GCOM1 c.388C > T, p.(Arg130*) variant was
observed in Family one in two DCM patients, and a homozygous
GCOM1 c.1150 A > T, p.(Lys384*) variant was observed in
Family two in four patients with cardiomyopathy. Both
variants cause a premature stop codon and are predicted to
cause loss of normal protein function either through protein
truncation (129/765 aa and 383/765 aa, respectively) or nonsense-
mediated mRNA decay from both of the alleles.
GCOM1 c.388C > T, p.(Arg130*) is located at exon 4/15 in the
canonical transcript of GCOM1, but two other RefSeq transcripts
of this gene (exon 4/14; NM_001018090, exon 4/13;
NM_001018091) are also affected. The variant also affects
exon 4/13 in MYZAP due to readthrough transcription. Six
individuals in the Genome Aggregation Database (gnomAD, n
> 120,000 exomes and >15,000 genomes) are heterozygous for
this GCOM1 c.388C > T, p.(Arg130*) variant. This variant is not
reported in the Finnish reference population, and the total allele
frequency is 0.00002387. GCOM1 c.1150 A > T, p.(Lys384*)
variant is located at exon 11/15 in the canonical transcript of
GCOM1 and also affects two other RefSeq transcripts of this gene
(exon 11/14; NM_001018090, exon 11/13; NM_001018091). Due
to readthrough transcription, this variant also affects exon 11/13
in MYZAP. In gnomAD, this variant is reported only in the
European Finnish cohort in one heterozygous individual. Allele
frequency in the Finnish population is 0.00004656, and the total
allele frequency is 0.000004073. No homozygous truncating
GCOM1 variant carriers are reported in the gnomAD
reference population. Individuals with severe pediatric diseases
have been excluded from these cohorts by database curators.
Altogether, GCOM1 c.388C > T, p.(Arg130*) was detected in
Family one in four individuals: two unaffected heterozygotes and
two homozygotes with DCM. One family member without the
variant had DCM secondary to lymphocytic myocarditis.
GCOM1 c.1150 A > T, p.(Lys384*) was detected in 11
individuals, four of them homozygotes. Two out of the four
GCOM1 p.(Lys384*) homozygotes suffered from
cardiomyopathy and died at young age, one fulfilled DCM
diagnostic criteria, and one received a primary diagnosis of
DCM, and later of ARVC. None of the heterozygotes in either
of the two families were affected. Pedigrees of families one and
two are shown in Figure 2.
Of the six affected individuals with homozygous truncation in
GCOM1, one had pacemaker (PM) and later heart
transplantation, four suffered from ventricular and atrial
arrhythmias, one had only ventricular arrhythmias, and one
had no recorded arrhythmias but suffered SCD (Table 1). Of
the six patients, three had AF or atrial flutter (AFL), four had non-
sustained ventricular tachycardia (NSVT), four had VES (>500/
24 h), two had SVES (>1500/24 h), and one hadmultiple VES and
SVES in stress-test. Six of nine heterozygotes had no recorded
arrhythmias, 2/9 had AF (at age >70). Two of three patients
without the variant had no arrhythmias, and 1/3 had AF and
NSVT. None of the heterozygotes had either PM or implantable
cardioverter-defibrillator (ICD), but one family member without
the variant had myocarditis-triggered DCM and received an ICD.
Three patients from Family one underwent CMR: two
homozygotes (II.1, II.2) and one patient without the variant
(II.4) with DCM secondary to lymphocytic myocarditis
(Figure 3). Both homozygotes had hypokinetic and dilated left
ventricles; right ventricles were normal. Extensive LGE was
observed in both; subepicardial LGE, especially in the lateral
wall, and intramyocardial LGE were observed. In II.4, both
ventricles were dilated and hypokinetic and extensive patchy
LGE were observed. PET-CT was later performed in all three.
In the homozygotes, no signs of inflammation or sarcoidosis were
observed. In the patient without the variant, findings compatible
with a mild inflammatory process were observed in the lateral
wall and septum. On echocardiography, two patients (F2: II.2,
II.4) had suboptimal left ventricular function, but also RVEDD
greater than LVEDD. Other homozygotes in both families had
normal right ventricular function.
Histological samples were available from five patients: four
homozygotes (F1: II.1, F2: II.4, II.9, II.10) and one genotype
negative (F1: II.4). EMB was taken from one genotype negative
patient and one homozygote, the whole heart was examined post-
mortem in two homozygotes, and after explantation in one
homozygote. Histology indicated no signs of inflammation in
any of the homozygotes, myocyte degeneration was observed in
all four homozygotes and fibrosis was observed in three. The
genotype negative patient had findings compatible with
lymphocytic myocarditis. Fibrofatty replacement of atria,
septum, and posterior wall were observed post-mortem in one
homozygous patient, whereas RV was unaffected.
Immunohistochemistry was conducted in the four
homozygotes and wild type control samples (Figure 4). Due
to poor quality and small sample size, immunohistochemistry
was not conducted for the EMB of F1 II.4. Myozap-staining of the
samples from GCOM1 homozygotes showed clear loss of staining
when compared to the intense brown staining in the wild-type
control myocardium samples. The loss of staining demonstrates
reduced expression in GCOM1 homozygotes.
Five of the six homozygotes had a cardiomyopathy diagnosis;
DCM was diagnosed at the ages of 24, 34, 36, and 37 One
homozygote was diagnosed with DCM at the age of 41 but
was later diagnosed with ARVC. The one homozygote who
did not have a cardiomyopathy diagnosis while living
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experienced SCD at the age of 24 and was diagnosed with
cardiomyopathy in autopsy. None of the nine heterozygous
family members fulfilled any cardiomyopathy criteria. One
family member (F1: II.4) without the variant had DCM
secondary to lymphocytic myocarditis. Due to fragmented
DNA in their sample, broad genetic testing could not be
conducted. In broad panel testing, the patient’s parents (F1:
I.1, I.2) were heterozygous for the GCOM1 variant, and did
not have any other potentially pathogenic variants that could
explain the heart failure in the daughter (II.4), who was
homozygous for wildtype alleles in GCOM1.
Based on the variant classification scheme that follows the
ACMG guidelines,GCOM1 c.388C > T, p.(Arg130*) andGCOM1
c.1150 A > T, p.(Lys384*) variants can be considered likely
pathogenic.
Family 1
The proband (II.1) was a 34-year-old female who received DCM
diagnosis at the age of 24. She had fluctuating Troponin I (TnI)
concentrations over the years; TnI was 2,358 ng/ L at its highest
(normal range <45 ng/ L). She had low voltage P-waves in an
otherwise normal ECG. Holter-monitoring demonstrated NSVT
and VES (1900/24 h). CMR demonstrated a dilated LV and
systolic dysfunction; RV was within normal limits. In LV, EF
was 38%, end-diastolic volume (EDV) was 242 ml (126 ml/ m2),
end-systolic volume (ESV) was 149 ml (78 ml/ m2), and stroke
volume (SV) was 93 ml. Right ventricular ejection fraction
(RVEF) was 54%, EDV was 163 ml (85 ml/ m2), ESV was
71 ml (37 ml/ m2), and SV was 92 ml. Lateral wall was thin;
basal thickness was around 4 mm, and apical thickness was
6 mm. Extensive circular subepicardial LGE was observed in
LV, but midmyocardial involvement and patchy LGE were
also detected. Segmental T1 native mapping times were
slightly increased in all segments referring to diffuse
myocardial fibrosis. Slight myocardial oedema was observed.
In EMB, no signs of myocarditis or sarcoidosis were seen. In
PET-CT, perfusion was decreased in the septum, especially in
anteroseptal regions; no sign of inflammatory process or
sarcoidosis were observed.
The brother (II.2) of the proband, a previously healthy 37-
year-old male, was diagnosed with DCM during this study. He
had been asymptomatic except for mild palpitations during stress.
FIGURE 2 | Pedigrees of two families. Family one is affected with GCOM1 c.388C > T, p.(Arg130*) variant, Family 2 withGCOM1 c.1150 A > T, p.(Lys384). Circles
represent women, squaresmen. Black symbols represent individuals who fulfil cardiomyopathy criteria. Grey symbol represents cardiomyopathy of other etiology. Arrow
indicates proband. Genotypes: + / + homozygous and + / - heterozygous for theGCOM1 c.1150 A > T, p.(Lys384*); + / +* homozygous and +/ −* heterozygous the for
GCOM1 c.388C > T, p.(Arg130*), − / − wild type allele. Clinical features are listed below the symbols; Age–age at the time of clinical examination or at the time of
death, LVEDD left ventricular end-diastolic diameter (mm), LVEF left ventricular ejection fraction (%), pacemaker/cardiac transplant: + indicates yes,–indicates no, ToF
Tetralogy of Fallot.
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TABLE 1 | The main clinical features of the probands and their relatives. Probands are marked in bold. Symbols and abbreviations: Age (M/F) age and sex (M: male/F: female); Genotype: +/ + homozygous and +/ −
heterozygous for theGCOM1 c.1150 A > T, p.(Lys384*); +/+* homozygous and +/-* heterozygous for theGCOM1 c.388C > T, p.(Arg130*), −/ −wild type allele; NA not available; AVB1 and AVB3 for atrioventricular block
1 and 3, LAHB for left anterior hemiblock, RBBB for right bundle branch block, SSS for sick sinus syndrome; Atrial arrhythmias–arrhythmias of atrial origin: SVES for supraventricular extrasystoles >100/24 h,†when observed
in stress-test, AF for atrial fibrillation, AFL for atrial flutter, AT for atrial tachycardia, SVT for supraventricular tachycardia; ventricular arrhythmias–arrhythmias of ventricular origin: VES for ventricular extrasystoles >100/24 h, †
when observed in stress-test, NSVT for non-sustained ventricular tachycardia; PM pacemaker, ICD implantable cardioverter-defibrillator; LVEDD left ventricular end-diastolic diameter (millimeters); LVEF left ventricular
ejection fraction (%); RVEDD right ventricular end-diastolic diameter (millimeters); Age at dg–age at the time of diagnosis of cardiomyopathy; Histology: + if endomyocardial biopsy was taken, ++ if the heart was examined


























34F +/+* No No NSVT, VES No 60 35 NA 24 + DCM Heart
transplant
I.1 79M +/−* No No No No 51 53 30
I.2 71F +/−* No No No No 47 67 31–33
II.2 38M +/+* No SVES VES No 62 40 23 37 DCM
II.4 F −/− AVB3 AF NSVT DDD-
ICD




72F +/+ No AF, AFL, AT NSVT, VES VVIR 56 43 57 41 ++ ARVC
I.1 79M − AVB1, RBBB,
LAHB
AF No No 60 64 NA 88
I.2 76F +/− SSS AF, SVT No No 52 52 NA 80
II.1 66F +/− RBBB SVT No No 57 53 NA
II.2 43M +/+ LAHB AF, AT, SVES NSVT, VES No 61 40 72 36 55 DCM Tetralogy of
FallotII.3 57M +/− No No No No 54 58 28
II.5 65M −/− No No No No 47 62 NA
II.6 59M −/− No No No No 52 60 NA
II.7 73M NA No No No No 42 NA NA
II.8 54F +/− No No No No 41 56 NA
II.9 M +/+ No No No No NA NA NA 24 ++ Affected SCD
II.10 M +/+ No AF, AFL,
SVES†
NSVT, VES† No NA NA NA 34 34 ++ Congestive
cardiomyopathy
III.1 19F NA No No No No 43 61 NA
III.2 15F NA No No No No 48 71 NA
III.3 50F +/− No No No No 52 60 NA
III.4 47F − No No No No 43 69 NA
III.5 15M NA No No No No 45 65 NA
III.6 19F NA No No No No 48 71 NA






































Holter-monitoring demonstrated VES (1028/24 h) and SVES
(1545/24 h). He had low voltage P-waves in an otherwise
normal ECG. TnI concentrations were elevated: 2,999 ng/ L at
its highest. On CMR, LV was dilated and hypokinetic, EF was
40%, EDVwas 250 ml (132 ml/ m2), ESV was 150 ml (79 ml/ m2),
and SV was 100 ml. RV was normal, RVEF was 60%, EDV was
167 ml (88 ml/ m2), ESV was 66 ml (35 ml/ m2), and SV was
101 ml. Wall thickness was 7–8 mm. Segmental T1 native
mapping times were increased in the inferior and lateral wall.
Extensive midmyocardial LGE was observed in septum;
subepicardial LGE was observed in basal and midventricular
regions. Increased extracellular volume compatible with
fibrosis or oedema was seen. No signs of inflammation or
sarcoidosis were observed in PET-CT.
The sister (II.4) not carrying the variant had DCM secondary
to lymphocytic myocarditis at the age of 41 and died at the age of
44 due to end-stage heart failure. She presented with advanced
disease already at the first time she sought medical treatment. She
suffered from AF and NSVT, in ECG she had prominent P-waves
and a 3-degree AV-block. She later received a pacemaker. Slightly
elevated and fluctuating Troponin T (TnT) levels were observed
over the years (TnT 98 ng/ L, normal range <14 ng/ L). Global
hypokinesia and dilated ventricles were observed in CMR. In LV,
EF was 18%, EDV was 404 ml (199 ml/ m2), ESV was 329 ml
(162 ml/ m2), and SV was 74 ml. In RV, EF was 28%, EDV was
266 ml (131 ml/ m2), ESV was 191 ml (94 ml/ m2), and SV 75 ml.
Reduced wall-thickness was observed, 12 mm in basal septum,
otherwise septal thickness was 6 mm, and inferolateral wall-
thickness was only 3 mm. Left ventricular myocardium was
abnormal and extensive patchy LGE was observed, transmural
LGE was observed in inferolateral akinetic region and was
deemed to be compatible with inflammatory process. EMBs
showed severe myocyte degeneration, lymphocytes, and mast
cells, compatible with lymphocytic myocarditis. PET-CT
demonstrated uneven perfusion in LV walls, deficiency was
also seen in apex, anterior and inferior walls, and inferior part
of the septum. Findings were compatible with mild inflammatory
process. She had poor compliance with the heart failure
treatment. She used antipsychotic medication for over a
decade for schizophrenia. Perphenazine was prescribed at the
age of 33 and was later changed to risperidone, which she used for
over 6 years. For 2 years she had quetiapine combined with
risperidone. A year before the first cardiac symptoms, the
medication was changed to paliperidone. Due to the poor
sample quality, no further genetic testing could be conducted
to detect possible pathogenic variants contributing to the disease.
The proband’s heterozygotic parents had normal findings in
cardiac evaluations. NGS panel testing was conducted on both
parents; no pathogenic/likely pathogenic or other promising
variants in known cardiomyopathy genes were found. The 79-
year-old father (I.1) had normal ECG. He has had some
palpitations but no recorded arrhythmias. On
echocardiography his LVEDD was 51 mm and LVEF was 53%.
Mother (I.2) was 71 years old; her ECG was normal, and she has
had no arrhythmias. On echocardiography, her LVEDD was
47 mm and LVEF was 67%. One sibling (II.3) was unavailable
for the study.
Family 2
The proband (II.4) was a 72-year-old female who received a DCM
diagnosis at the age of 41 and an ARVC diagnosis at the age of 52.
Echocardiography demonstrated biventricular dilatation,
LVEDD was 56 mm, RVEDD was 57 mm, and LVEF was
43%. She had arrhythmias at stress and rest, Holter-
monitoring demonstrated NSVT and VES (10,000/24 h). She
had a tendency for atrial arrhythmias, AFL, AF, and AT. She
received a pacemaker and later a heart transplant at the age of 52.
Her ECG showed low-voltage P-waves and T-wave inversions in
V1-V3. Her explanted heart was examined, no coronary artery
disease was observed, and valves were structurally normal. RV
FIGURE 3 |CMR images of the proband (Family 1, II.1), affected family member with homozygousGCOM1 p.(Arg130*) (Family 1, II.2), and affected family member
with no familial mutation but DCM secondary to lymphocytic myocarditis (Family 1, II.4). Both homozygotes (II.1, II.2) presented mid-wall LGE in the septum (arrows) and
subepicardial enhancement in the inferolateral areas (dashed arrow). The genotype negative patient (II.4) exhibited multifocal and patchy LGE involving several layers of
the myocardium.
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FIGURE 4 | Histological samples. Myozap-staining of myocardial samples from homozygotes (Family 1: II.1 and Family 2: II.4, II.9, II.10) show clear loss of staining
when compared to the wild type GCOM1 control samples. Controls with primary antibody omitted or substituted with rabbit non-immune IgG showed no staining (Data
not shown).
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wall-thickness was reduced to only 3–4 mm, LV wall thickness
was 15 mm. On histology, thick fibrotic endocardium was
observed as well as severe myocyte degeneration. There were
no signs of inflammation or myocardial infarction.
One brother (II.2) received a DCM diagnosis at the age of 36
and died at the age of 55. On echocardiography wall thickness was
normal, LVEDD was 61 mm, LVEF was 40%, and RVEDD was
72 mm. He suffered from presyncope, AF, and AT; in ECG he had
low voltage P-waves. In Holter-monitoring, VES (600/24 h),
SVES (1600/24 h), and NSVT were observed.
Another brother (II.9) was apparently healthy but died
suddenly at the age of 24. He had no history of cardiac
disease, syncope, or arrhythmias. An autopsy was performed,
and histology showed significant fibrotic changes in epicardium
and myocardium; there was no sign of inflammation. Another
brother (II.10) died at the age of 34. He had congestive
cardiomyopathy and suffered from AF, AFL, and NSVT. He
had multiple SVES and VES in stress-test. Autopsy was
performed and on histology, fibrofatty replacement of the
myocardium was seen mainly in the septum and posterior
wall, but some changes were seen also in both atria. No
changes were observed in the right ventricle. Histological
samples of brothers II.9 and II.10 were compared, and the
findings were similar.
The proband’s father (I.1) died at the age of 88. On
echocardiography, his LVEDD was 60 mm and LVEF was
64%. He suffered from AF and had right bundle branch block
(RBBB) and left anterior hemiblock (LAHB) in ECG. The mother
(I.2) died at the age of 80. On echocardiography, her LVEDD was
52 mm and LVEF was 52%. She had moderate mitral
regurgitation and mild to moderate tricuspid-valve
insufficiency. She suffered from AF and SVT, and, in Holter-
monitoring, had findings suggestive of sick sinus syndrome.
Other relatives were also evaluated as a part of this study. One
relative (II.1) had surgically repaired tetralogy of Fallot; cardiac
findings were deemed to be associated with the postoperative
state and congenital defect. All other relatives had normal
findings in cardiac evaluations and were deemed unaffected.
DISCUSSION
In this study, we describe the cardiac phenotypes of six
cardiomyopathy patients with homozygous truncating GCOM1
variants from two families. All nine heterozygous individuals in
the families were unaffected. The inheritance pattern is autosomal
recessive. To our knowledge, neither of these GCOM1 variants
have been previously reported in the literature.
GCOM1 and Human Cardiomyopathy
ClinVar does not contain any homozygous truncating variants in
GCOM1; however, one truncating variant in one of the read
through transcripts (MYZAP) is reported in a patient with DCM
(ID: 523392) (March 2021).
All patients homozygous for either of the twoGCOM1 variants
fulfilled the diagnostic criteria of DCM or ARVC. Some of these
patients remained fairly asymptomatic even though the disease
had advanced; for example, in Family one patient II.2 reported no
symptoms but had suboptimal left ventricular function when
primary cardiac evaluation was conducted. The phenotype
became evident in both families by the age of 41; age of
diagnosis did not vary greatly: the youngest was 24 years old
and oldest was 41 at the time of diagnosis.
One deceased patient (Family 1, II.4) with a negative genotype
fulfilled DCM imaging criteria but had histological findings
compatible with lymphocytic myocarditis. Use of antipsychotic
medication could have contributed to the phenotype. Although
rare, quetiapine and risperidone have some level of associated risk
with myocarditis and cardiomyopathy. (Coulter et al., 2001;
Stoner, 2017). The EMB available was of poor quality, and we
were not able to do further testing to confirm any other possible
variants contributing to the patient’s cardiomyopathy. NGS panel
testing was conducted on the parents, but no pathogenic/likely
pathogenic or other promising variants in known
cardiomyopathy genes were found.
Fluctuating TnI levels were seen in some patients over the
years, troponin levels were quite high in some cases but
normalized in follow-up. The relative lack of heart failure
symptoms, young age, and high troponin levels could mislead
clinicians in their primary diagnosis, especially if no family
history is available. Myocarditis was sometimes suspected
initially, but no sign of inflammation was observed in further
examination. Inflammation could be related to the
pathophysiology of the cardiomyopathy, but further studies
are still needed to elucidate the background of these
observations. In a small case report, reported that over half of
their patients with clinically suspected myocarditis had a
pathogenic or likely pathogenic variant in ARVC-associated
genes. (Ader et al., 2020). They speculated that acute
myocarditis could be the first clinical manifestation of
inherited cardiomyopathy, especially arrhythmogenic
cardiomyopathy. (Ader et al., 2020).
GCOM1/MYZAP variants have not been published as a cause
of human cardiomyopathy, but at least one variant has been
reported in association with atrial arrhythmias. In a meta-analysis
of genome-wide association study, a MYZAP p. Gln254Pro
missense variant was associated with increased risk of SSS and
AF. (Thorolfsdottir et al., 2018). In our study, homozygotes seem
to have a tendency for atrial arrhythmias. In 12-lead ECG, we
noticed low amplitude P-waves in most of the precordial and
extremity leads in homozygotes. The same was not observed in
heterozygotes or family members not carrying the variant.
Five of the six homozygotes meet some cardiomyopathy
criteria. Heart failure is the leading clinical feature, even
though the patients may remain fairly asymptomatic. SCD was
observed in one GCOM1 homozygote, and post-mortem
examination revealed fibrosis in the heart. The importance of
the arrhythmogenic side of the phenotype and the risk of fatal
arrhythmias remains unclear. Our findings confirm the GCOM1
variants as a cause of human cardiomyopathy.
Animal Models
MYZAP, one of the components in GRINL1A CTU, has been
linked to cardiomyopathy in zebrafish and mice. (Seeger et al.,
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2010; Frank et al., 2014). Seeger et al. showed that knock-down of
MYZAP in zebrafish results in cardiomyopathy with severe
systolic dysfunction without significant cardiac enlargement or
disturbing the cardiac development. (Seeger et al., 2010).
Overexpression of Myozap, which is a protein encoded by
MYZAP, caused cardiomyopathy with hypertrophy and LV
enlargement in mice, and exercise accelerated these changes.
(Frank et al., 2014). The cardiac phenotype in these mice
mimicked desmin-related cardiomyopathies; even though
desmin was not directly involved, protein aggregates
containing Myozap and other intercalated disc (ID) proteins,
such as desmoplakin, were present. (Frank et al., 2014).
Genetic Background of DCM and ARVC
Classification of cardiomyopathies are mainly based on
phenotypic and cardiac imaging criteria; for example in
ARVC, the diagnosis is based on a set of complex criteria.
(Elliott et al., 2008; Marcus et al., 2010; Corrado et al., 2020).
Some overlap in phenotypic expression of cardiomyopathies can
be seen, and overlap in genetic background has become evident as
well. (Hershberger et al., 2013). The increasing amount of
reported ARVC patients with greater LV involvement or
biventricular disease has led to the proposition of
arrhythmogenic cardiomyopathy. (Basso et al., 2012; Towbin
et al., 2019). AC is a heterogeneous disorder associated with
ventricular arrhythmias, systolic dysfunction, and increased risk
of SCD. The estimated prevalence of AC ranges from 1:1,000 to 1:
5,000. (Basso et al., 2012; Jacoby andMcKenna, 2012). The lack of
consensus criteria might lead to under-recognition of the disease.
Both ARVC and DCM are primarily inherited in an autosomal
dominant pattern and there is some overlap in the genetic
background. (Hershberger et al., 2010; Jacoby and McKenna,
2012; Campuzano et al., 2013; Hershberger et al., 2013; McNally
et al., 2013). Autosomal recessive forms of both diseases are reported,
although they are rarer. (Keller et al., 2012; Campuzano et al., 2013;
McNally et al., 2013; McNally and Mestroni, 2017). The genetic
etiology of DCM is broad and variants are identified in genes
encoding sarcomeric proteins, cytoskeleton, ion channels, nuclear
envelope, and intercellular junction proteins such as TTN, LMNA,
DSP,MYH7, FLNC, TNNT2, RBM20, DES, TPM1, FLNC, andDMD.
(Herman et al., 2012;McNally et al., 2013;Mestroni and Taylor, 2013;
Akinrinade et al., 2015). Most ARVC/AC pathological variants are
reported in genes encoding the proteins of the desmosome, including
PKP2, DSP, DSG2, JUP, and DSC2. (Jacoby and McKenna, 2012;
Campuzano et al., 2013). AC- and DCM-associated genes, such as
DSP, DES, and PKP2, encode components of the ID. (Basso et al.,
2012; Vermij et al., 2017). Remodeling of the ID has been shown in
association with ARVC. (Basso et al., 2006).
The cardiac ID is a complex structure classically considered to
consist of three main structures: desmosomes, adherens
junctions, and gap junctions. Previously these three structures
have been considered as individual units, but it has become
evident that all components of the ID work as one functional
unit. (Vermij et al., 2017). The main function of the ID is to attach
adjacent cardiomyocytes and have the cardiac tissue work as a
synchronized unit both mechanically and electrically. (Vermij
et al., 2017). Because of its function, cardiac ID is considered to be
in the center of pathophysiological mechanisms of
cardiomyopathies. (Basso et al., 2006; Manring et al., 2018).
Conjoined Genes
The GRINL1A CTU on chromosome 15q21.3-q22.1 is composed
of two conjoined genes; the upstream centromeric group was
originally referred to as Gup and later named MYZAP, and the
downstream genewas referred to as Gdown, later named POLR2M.
(Roginski et al., 2001; Roginski et al., 2004; Hu et al., 2006; Seeger
et al., 2010). The CTU contains at least 28 exons that can be divided
to three groups: upstream (exons 1–15), middle (exons 16–19), and
downstream (exons 20–28). (Roginski et al., 2004). There are
multiple start sites for transcription; upstream promoter (Pu) is
located in exon one and downstream promoter (Pd) in exon 20.
(Roginski et al., 2004). Pd transcription can initiate at two principal
sites. (Roginski et al., 2004).
Transcription of the POLR2M initiates at the Pd and the
transcripts contain only exons from the downstream group
(Coulter et al., 2001; Seeger et al., 2010; Richards et al., 2015;
Stoner, 2017; Thorolfsdottir et al., 2018; Ader et al., 2020;
Decloaking Chamber, 2021; Peroxidase Blocking Solution, 2021;
Rabbit IgG, 2021). POLR2M encodes the protein Gdown1, which is
the 13th subunit of a specific form of RNApolymerase II and acts as
its suppressor. (Hu et al., 2006). POLR2M has not been shown to
cause monogenic disease in humans.
MYZAP transcription initiates at the Pu, and the transcripts
contain only certain exons from the upstream group ((Codd et al.,
1989; Mestroni et al., 1999; Elliott et al., 2008; Hershberger et al.,
2009; Hershberger et al., 2010; Marcus et al., 2010; Basso et al.,
2012; Campuzano et al., 2013; Hershberger et al., 2013; McNally
et al., 2013), (Towbin et al., 2019), (Corrado et al., 2020), and
(Hershberger et al., 2018)). MYZAP encodes the Gup1 protein,
also called Myozap (myocardium-enriched zona occludens-1-
associated protein), which is highly conserved and strongly
expressed in the myocardial tissue. (Seeger et al., 2010). In an
immunohistochemical analysis of mouse cardiomyocytes,
Myozap binds directly to desmoplakin and ZO-1, which are
components of the ID. (Seeger et al., 2010). Myozap also
localized in ID in immunoelectron microscopy of bovine
heart. (Seeger et al., 2010). Yeast 2-hybrid analysis
demonstrated that amino acids 91–250 of Myozap are
required for binding to ZO-1. (Seeger et al., 2010).
Transcription of theGCOM1 combined gene initiates at the Pu
and then splices to middle or downstream exons, transcription is
terminated at the downstream exons (23, 24, or 28). (Roginski
et al., 2004). The combined transcripts include exons from all
three groups; upstream exons from the MYZAP gene,
downstream exons from the POLR2M gene as well as exons
from the middle group (Roginski et al., 2001; Roginski et al., 2004;
Hu et al., 2006; Roginski et al., 2018). (Roginski et al., 2004) Due
to the inclusion of exons 16 and 19a and the use of different
frames in downstream exons, GCOM1 amino acid translations
contain residues that are not present in neither MYZAP nor
POLR2M. (Roginski et al., 2004).
Although the genetic background of cardiomyopathies has been
under investigation for decades andmuch progress has beenmade,
many patients undergoing genetic testing are still left without a
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genetic diagnosis. It is important to seek new candidate genes in
addition to novel variants in known disease-causing genes when
targeted gene panels do not yield a positive outcome, especially if
familial cardiomyopathy is suspected. Since genetic testing
uncovers a large number of variants at genome level, e.g.,
>30,000 variants per average exome, the analysis is typically
limited to rare variants or less rare variant pairs when assuming
dominant or recessive inheritance. In case of these CTU genes
(GCOM1, MYZAP, POLR2M), variants can be randomly called
into different genes within the CTU, leaving the variant scientist or
geneticist in a situation where they do not discover a variant pair
due to an annotation issue. Thus, cardiomyopathy related to this
CTU may be more common than discovered so far.
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